- Kalytera Therapeutics (TSXV:KLY) has received a Notice of Allowance for its pending US patent to treat graft versus host disease
- The company expects the approval of their corresponding EU patent application later this month
- Kalytera already has 2 US patents which provide exclusive worldwide rights to use CBD as a GVHD prevention and treatment
- The company has obtained European and US drug designations which may help fight GVHD, and provide market exclusivity
- Kalytera’s share price remains unchanged, and is currently trading at 4.5 cents per share
Pharmaceutical company Kalytera Therapeutics (KLY) has received a Notice of Allowance for its latest US patent application.
Once finalised, the patent will cover Kalytera’s use of cannabidiol (CBD) to prevent and treat graft versus host disease (GVHD).
GVHD is a serious condition that results from complications after a bone marrow transplant.
In roughly 50% of bone marrow transplants, cells from the bone marrow donor will attack the patient’s body. This can affect the skin, gastrointestinal tract, liver, lungs, and eyes.
While the level of suffering varies, the condition can result in infection, reduced quality of life, acute and chronic illness, disability, and death.
Kalytera already has two US patents which provide exclusive worldwide rights to use CBD as a GVHD prevention and treatment. Once followed up and finalised, this new patent will update the current portfolio.
Kalytera’s President and CEO, Robert Farrell, described the company’s ongoing plan to patent the CBD treatment internationally.
“In addition to this new US patent, we anticipate that our EU patent application covering the use of CBD in the prevention and treatment of GVHD will be granted later this month.”
Kalytera has also obtained 4 orphan drug designations for the prevention and treatment of GVHD in Europe and the US.
These assets may provide the company with 7 years of US market exclusivity, and 10 years of European market exclusivity.
This will be dependent on regulatory approval of the CBD products Kalytera will use to prevent and treat GVHD.
Kalytera’s share price remains unchanged, and is currently trading at 4.5 cents per share.